Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Pediatric Nephrology
Erschienen in: Pediatric Nephrology 6/2022

06.09.2021 | Educational Review

Pediatric Onco-Nephrology: Time to Spread the Word-Part II: Long-Term Kidney Outcomes in Survivors of Childhood Malignancy and Malignancy after Kidney Transplant

verfasst von: Arwa Nada, Jennifer G Jetton

Erschienen in: Pediatric Nephrology | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

Onco-nephrology is a recent and evolving medical subspecialty devoted to the care of patients with kidney disease and unique kidney-related complications in the context of cancer and its treatments, recognizing that management of kidney disease as well as the cancer itself will improve survival and quality of life. While this area has received much attention in the adult medicine sphere, similar emphasis in the pediatric realm has not yet been realized. As in adults, kidney involvement in children with cancer extends beyond the time of initial diagnosis and treatment. Many interventions, such as chemotherapy, stem cell transplant, radiation, and nephrectomy, have long-term kidney effects, including the development of chronic kidney disease (CKD) with subsequent need for dialysis and/or kidney transplant. Thus, with the improved survival of children with malignancy comes the need for ongoing monitoring of kidney function and early mitigation of kidney-related comorbidities. In addition, children with kidney transplant are at higher risk of developing malignancies than their age-matched peers. Pediatric nephrologists thus need to be aware of issues related to cancer and its treatments as they impact their own patients. These facts emphasize the necessity of pediatric nephrologists and oncologists working closely together in managing these children and highlight the importance of bringing the onco-nephrology field to our growing list of pediatric nephrology subspecialties.
Literatur
1.
2.
3.
4.
Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW et al (2003) National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139:137–147PubMedCrossRef
5.
Robison LL, Armstrong GT, Boice JD, Chow EJ, Davies SM, Donaldson SS et al (2009) The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol 27:2308–2318PubMedPubMedCentralCrossRef
6.
Gutierrez-Millet V, Nieto J, Praga M, Usera G, Martinez MA, Morales JM (1986) Focal glomerulosclerosis and proteinuria in patients with solitary kidneys. Arch Intern Med 146:705–709PubMedCrossRef
7.
Knijnenburg SL, Jaspers MW, van der Pal HJ, Schouten-van Meeteren AY, Bouts AH, Lieverst JA et al (2012) Renal dysfunction and elevated blood pressure in long-term childhood cancer survivors. Clin J Am Soc Nephrol 7:1416–1427PubMedPubMedCentralCrossRef
8.
Interiano RB, Delos Santos N, Huang S, Srivastava DK, Robison LL, Hudson MM et al (2015) Renal function in survivors of nonsyndromic Wilms tumor treated with unilateral radical nephrectomy. Cancer 121:2449–2456PubMedCrossRef
9.
de Graaf SS, van Gent H, Reitsma-Bierens WC, van Luyk WH, Dolsma WV, Postma A (1996) Renal function after unilateral nephrectomy for Wilms’ tumour: the influence of radiation therapy. Eur J Cancer 32A:465–469PubMedCrossRef
10.
Finklestein JZ, Norkool P, Green DM, Breslow N, D'Angio GJ (1993) Diastolic hypertension in Wilms’ tumor survivors: a late effect of treatment? A report from the National Wilms’ Tumor Study Group. Am J Clin Oncol 16:201–205PubMedCrossRef
11.
12.
Skinner R, Cotterill SJ, Stevens MC (2000) Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group. Br J Cancer 82:1636–1645PubMedPubMedCentralCrossRef
13.
Suarez A, McDowell H, Niaudet P, Comoy E, Flamant F (1991) Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report. J Clin Oncol 9:2177–2182PubMedCrossRef
14.
Berrak SG, Pearson M, Berberoglu S, Ilhan IE, Jaffe N (2005) High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity. Pediatr Blood Cancer 44:215–219PubMedCrossRef
15.
Ho PT, Zimmerman K, Wexler LH, Blaney S, Jarosinski P, Weaver-McClure L et al (1995) A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults. Cancer 76:2557–2564PubMedCrossRef
16.
Latcha S, Jaimes EA, Patil S, Glezerman IG, Mehta S, Flombaum CD (2016) Long-term renal outcomes after cisplatin treatment. Clin J Am Soc Nephrol 11:1173–1179PubMedPubMedCentralCrossRef
17.
Brock PR, Koliouskas DE, Barratt TM, Yeomans E, Pritchard J (1991) Partial reversibility of cisplatin nephrotoxicity in children. J Pediatr 118:531–534PubMedCrossRef
18.
McMahon KR, Harel-Sterling M, Pizzi M, Huynh L, Hessey E, Zappitelli M (2018) Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study. Pediatr Nephrol 33:2311–2320PubMedCrossRef
19.
Widemann BC, Balis FM, Kempf-Bielack B, Bielack S, Pratt CB, Ferrari S et al (2004) High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 100:2222–2232PubMedCrossRef
20.
Gronroos MH, Jahnukainen T, Mottonen M, Perkkio M, Irjala K, Salmi TT (2008) Long-term follow-up of renal function after high-dose methotrexate treatment in children. Pediatr Blood Cancer 51:535–539PubMedCrossRef
21.
Van Why SK, Friedman AL, Wei LJ, Hong R (1991) Renal insufficiency after bone marrow transplantation in children. Bone Marrow Transplant 7:383–388PubMed
22.
Kist-van Holthe JE, van Zwet JM, Brand R, van Weel MH, Vossen JM, van der Heijden AJ (1998) Bone marrow transplantation in children: consequences for renal function shortly after and 1 year post-BMT. Bone Marrow Transplant 22:559–564PubMedCrossRef
23.
Frisk P, Bratteby LE, Carlson K, Lonnerholm G (2002) Renal function after autologous bone marrow transplantation in children: a long-term prospective study. Bone Marrow Transplant 29:129–136PubMedCrossRef
24.
Patzer L, Ringelmann F, Kentouche K, Fuchs D, Zintl F, Brandis M et al (2001) Renal function in long-term survivors of stem cell transplantation in childhood. A prospective trial. Bone Marrow Transplant 27:319–327PubMedCrossRef
25.
Hoffmeister PA, Hingorani SR, Storer BE, Baker KS, Sanders JE (2010) Hypertension in long-term survivors of pediatric hematopoietic cell transplantation. Biol Blood Marrow Transpl 16:515–524CrossRef
26.
Abboud I, Peraldi MN, Hingorani S (2012) Chronic kidney diseases in long-term survivors after allogeneic hematopoietic stem cell transplantation: monitoring and management guidelines. Semin Hematol 49:73–82PubMedCrossRef
27.
Hingorani S, Gooley T, Pao E, Sandmaier B, McDonald G (2014) Urinary cytokines after HCT: evidence for renal inflammation in the pathogenesis of proteinuria and kidney disease. Bone Marrow Transplant 49:403–409PubMedCrossRef
28.
Cohen EP (2000) Radiation nephropathy after bone marrow transplantation. Kidney Int 58:903–918PubMedCrossRef
29.
Lawton CA, Cohen EP, Barber-Derus SW, Murray KJ, Ash RC, Casper JT et al (1991) Late renal dysfunction in adult survivors of bone marrow transplantation. Cancer 67:2795–2800PubMedCrossRef
30.
Cohen EP, Lawton CA, Moulder JE (1995) Bone marrow transplant nephropathy: radiation nephritis revisited. Nephron 70:217–222PubMedCrossRef
31.
Pettitt AR, Clark RE (1994) Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant 14:495–504PubMed
32.
Juckett M, Perry EH, Daniels BS, Weisdorf DJ (1991) Hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant 7:405–409PubMed
33.
Takatsuka H, Takemoto Y, Okamoto T, Fujimori Y, Tamura S, Wada H et al (1999) Thrombotic microangiopathy following allogeneic bone marrow transplantation. Bone Marrow Transplant 24:303–306PubMedCrossRef
34.
Antignac C, Gubler MC, Leverger G, Broyer M, Habib R (1989) Delayed renal failure with extensive mesangiolysis following bone marrow transplantation. Kidney Int 35:1336–1344PubMedCrossRef
35.
El-Seisi S, Gupta R, Clase CM, Forrest DL, Milandinovic M, Couban S (2003) Renal pathology at autopsy in patients who died after hematopoietic stem cell transplantation. Biol Blood Marrow Transpl 9:683–688CrossRef
36.
Moulder JE, Fish BL, Cohen EP (1998) Radiation nephropathy is treatable with an angiotensin converting enzyme inhibitor or an angiotensin II type-1 (AT1) receptor antagonist. Radiother Oncol 46:307–315PubMedCrossRef
37.
Kemper MJ, Gungor T, Halter J, Schanz U, Neuhaus TJ (2007) Favorable long-term outcome of nephrotic syndrome after allogeneic hematopoietic stem cell transplantation. Clin Nephrol 67:5–11PubMedCrossRef
38.
Colombo AA, Rusconi C, Esposito C, Bernasconi P, Caldera D, Lazzarino M et al (2006) Nephrotic syndrome after allogeneic hematopoietic stem cell transplantation as a late complication of chronic graft-versus-host disease. Transplantation 81:1087–1092PubMedCrossRef
39.
Srinivasan R, Balow JE, Sabnis S, Lundqvist A, Igarashi T, Takahashi Y et al (2005) Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation. Br J Haematol 131:74–79PubMedCrossRef
40.
Chien YH, Lin KH, Lee TY, Lu MY, Tsau YK (2000) Nephrotic syndrome in a bone marrow transplant recipient without chronic graft-versus-host disease. J Formos Med Assoc 99:503–506PubMed
41.
Hiesse C, Goldschmidt E, Santelli G, Charpentier B, Machover D, Fries D (1988) Membranous nephropathy in a bone marrow transplant recipient. Am J Kidney Dis 11:188–191PubMedCrossRef
42.
Mathieson PW (2003) Immune dysregulation in minimal change nephropathy. Nephrol Dial Transplant 18(Suppl 6):vi26–vi29PubMed
43.
Rizzo JD, Wingard JR, Tichelli A, Lee SJ, Van Lint MT, Burns LJ et al (2006) Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transpl 12:138–151CrossRef
44.
Cassady JR (1995) Clinical radiation nephropathy. Int J Radiat Oncol Biol Phys 31:1249–1256PubMedCrossRef
45.
46.
Bolling T, Schuck A, Pape H, Rube C, Meyer FM, Martini C et al (2007) Register for the evaluation of side effects after radiation in childhood and adolescence--first results. Klin Padiatr 219:139–145PubMedCrossRef
47.
Carrie C, Thomas P (2008) The Pediatric Radiation Oncology Society (PROS): why? Int J Radiat Oncol Biol Phys 71:666PubMedCrossRef
48.
Ritchey ML, Green DM, Thomas PR, Smith GR, Haase G, Shochat S et al (1996) Renal failure in Wilms’ tumor patients: a report from the National Wilms’ Tumor Study Group. Med Pediatr Oncol 26:75–80PubMedCrossRef
49.
Mitus A, Tefft M, Fellers FX (1969) Long-term follow-up of renal functions of 108 children who underwent nephrectomy for malignant disease. Pediatrics 44:912–921PubMedCrossRef
50.
Krochak RJ, Baker DG (1986) Radiation nephritis. Clinical manifestations and pathophysiologic mechanisms. Urology 27:389–393PubMedCrossRef
51.
52.
White DC (1976) The histopathologic basis for functional decrements in late radiation injury in diverse organs. Cancer 37(2 Suppl):1126–1143PubMedCrossRef
53.
Choi KL, Bakris GL (2005) Hypertension treatment guidelines: practical implications. Semin Nephrol 25:198–209PubMedCrossRef
54.
Batabyal P, Chapman JR, Wong G, Craig JC, Tong A (2012) Clinical practice guidelines on wait-listing for kidney transplantation: consistent and equitable? Transplantation 94:703–713PubMedCrossRef
55.
Chapman JR, Sheil AG, Disney AP (2001) Recurrence of cancer after renal transplantation. Transplant Proc 33:1830–1831PubMedCrossRef
56.
Penn I (1993) The effect of immunosuppression on pre-existing cancers. Transplantation 55:742–747PubMedCrossRef
57.
Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, Snyder JJ et al (2011) Spectrum of cancer risk among US solid organ transplant recipients. JAMA 306:1891–1901PubMedPubMedCentralCrossRef
58.
Collett D, Mumford L, Banner NR, Neuberger J, Watson C (2010) Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant 10:1889–1896PubMedCrossRef
59.
Samuel SM, Tonelli MA, Foster BJ, Alexander RT, Nettel-Aguirre A, Soo A et al (2011) Survival in pediatric dialysis and transplant patients. Clin J Am Soc Nephrol 6:1094–1099PubMedPubMedCentralCrossRef
60.
Tessari G, Naldi L, Boschiero L, Minetti E, Sandrini S, Nacchia F et al (2013) Incidence of primary and second cancers in renal transplant recipients: a multicenter cohort study. Am J Transplant 13:214–221PubMedCrossRef
61.
Debray D, Baudouin V, Lacaille F, Charbit M, Rivet C, Harambat J et al (2009) De novo malignancy after solid organ transplantation in children. Transplant Proc 41:674–675PubMedCrossRef
62.
Simard JF, Baecklund E, Kinch A, Brattstrom C, Ingvar A, Molin D et al (2011) Pediatric organ transplantation and risk of premalignant and malignant tumors in Sweden. Am J Transplant 11:146–151PubMedCrossRef
63.
Ploos van Amstel S, Vogelzang JL, Starink MV, Jager KJ, Groothoff JW (2015) Long-term risk of cancer in survivors of pediatric ESRD. Clin J Am Soc Nephrol 10:2198–2204PubMedPubMedCentralCrossRef
64.
Mucha K, Foroncewicz B, Ziarkiewicz-Wroblewska B, Krawczyk M, Lerut J, Paczek L (2010) Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease? Nephrol Dial Transplant 25:2089–2098PubMedCrossRef
65.
Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K (2005) Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 80:1233–1243PubMedCrossRef
66.
McDonald RA, Smith JM, Ho M, Lindblad R, Ikle D, Grimm P et al (2008) Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 8:984–989PubMedCrossRef
67.
Haque T, Crawford DH (1998) Role of donor versus recipient type Epstein-Barr virus in post-transplant lymphoproliferative disorders. Springer Semin Immunopathol 20:375–387PubMedCrossRef
68.
Quinlan SC, Pfeiffer RM, Morton LM, Engels EA (2011) Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol 86:206–209PubMedPubMedCentralCrossRef
69.
Schober T, Framke T, Kreipe H, Schulz TF, Grosshennig A, Hussein K et al (2013) Characteristics of early and late PTLD development in pediatric solid organ transplant recipients. Transplantation 95:240–246PubMedCrossRef
70.
Hart A, Smith JM, Skeans MA, Gustafson SK, Stewart DE, Cherikh WS et al (2017) OPTN/SRTR 2015 Annual Data Report: kidney. Am J Transplant 17(Suppl 1):21–116PubMedPubMedCentralCrossRef
71.
Dharnidharka VR (2010) Epidemiology of PTLD. In: VRGM D, Webber SA (eds) Post transplant lymphoproliferative disorders, vol 1. Springer-Verlag, Berlin-Heidelberg, pp 17–28CrossRef
72.
van der Molen AJ, Reimer P, Dekkers IA, Bongartz G, Bellin MF, Bertolotto M, Clement O, Heinz-Peer G, Stacul F, Webb JAW, Thomsen HS (2018) Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients : Recommendations for updated ESUR Contrast Medium Safety Committee guideline. Eur Radiol 28:2856–2869PubMedPubMedCentralCrossRef
73.
Allen UD, Preiksaitis JK, AST Infectious Diseases Community of Practice (2013) Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation. Am J Transplant 13(Suppl 4):107–120PubMedCrossRef
74.
Al-Mansour Z, Nelson BP, Evens AM (2013) Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep 8:173–183PubMedPubMedCentralCrossRef
75.
Bingler MA, Feingold B, Miller SA, Quivers E, Michaels MG, Green M et al (2008) Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children. Am J Transplant 8:442–445PubMedCrossRef
76.
Dharnidharka VR, Sullivan EK, Stablein DM, Tejani AH, Harmon WE, North American Pediatric Renal Transplant Cooperative Study (2001) Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 71:1065–1068PubMedCrossRef
77.
Mathew T, Kreis H, Friend P (2004) Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transpl 18:446–449CrossRef
78.
Kahan BD, Yakupoglu YK, Schoenberg L, Knight RJ, Katz SM, Lai D et al (2005) Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 80:749–758PubMedCrossRef
79.
Kirk AD, Cherikh WS, Ring M, Burke G, Kaufman D, Knechtle SJ et al (2007) Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 7:2619–2625PubMedPubMedCentralCrossRef
80.
Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW (2003) Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 76:1289–1293PubMedCrossRef
81.
Funch DP, Ko HH, Travasso J, Brady J, Kew CE 2nd, Nalesnik MA et al (2005) Posttransplant lymphoproliferative disorder among renal transplant patients in relation to the use of mycophenolate mofetil. Transplantation 80:1174–1180PubMedCrossRef
82.
83.
Bustami RT, Ojo AO, Wolfe RA, Merion RM, Bennett WM, McDiarmid SV et al (2004) Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 4:87–93PubMedCrossRef
84.
Opelz G, Henderson R (1993) Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 342:1514–1516PubMedCrossRef
85.
Grinyo J, Charpentier B, Pestana JM, Vanrenterghem Y, Vincenti F, Reyes-Acevedo R et al (2010) An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 90:1521–1527PubMedCrossRef
86.
Kidney Disease: Improving Global Outcomes Transplant Work Group (2009) KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9(Suppl 3):S1–S155
87.
Kasiske BL, Vazquez MA, Harmon WE, Brown RS, Danovitch GM, Gaston RS et al (2000) Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 11(Suppl 15):S1–S86
88.
Green M, Reyes J, Webber S, Rowe D (2001) The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation. Transpl Infect Dis 3:97–103PubMedCrossRef
89.
Hocker B, Bohm S, Fickenscher H, Kusters U, Schnitzler P, Pohl M et al (2012) (Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation. Transpl Int 25:723–731PubMedCrossRef
90.
Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD (2005) Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 5:2894–2900PubMedCrossRef
91.
Meng Q, Hagemeier SR, Fingeroth JD, Gershburg E, Pagano JS, Kenney SC (2010) The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production. J Virol 84:4534–4542PubMedPubMedCentralCrossRef
92.
Green M, Michaels MG, Katz BZ, Burroughs M, Gerber D, Shneider BL et al (2006) CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Am J Transplant 6:1906–1912PubMedCrossRef
93.
AlDabbagh MA, Gitman MR, Kumar D, Humar A, Rotstein C, Husain S (2017) The role of antiviral prophylaxis for the prevention of Epstein-Barr virus-associated posttransplant lymphoproliferative disease in solid organ transplant recipients: a systematic review. Am J Transplant 17:770–781PubMedCrossRef
94.
Rees L, Tizard EJ, Morgan AJ, Cubitt WD, Finerty S, Oyewole-Eletu TA et al (2009) A phase I trial of Epstein-Barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation. Transplantation 88:1025–1029PubMedCrossRef
95.
Tsai DE, Hardy CL, Tomaszewski JE, Kotloff RM, Oltoff KM, Somer BG et al (2001) Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 71:1076–1088PubMedCrossRef
96.
Reshef R, Vardhanabhuti S, Luskin MR, Heitjan DF, Hadjiliadis D, Goral S et al (2011) Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder (bigstar). Am J Transplant 11:336–347PubMedPubMedCentralCrossRef
97.
Dharnidharka VR, Martz KL, Stablein DM, Benfield MR (2011) Improved survival with recent post-transplant lymphoproliferative disorder (PTLD) in children with kidney transplants. Am J Transplant 11:751–758PubMedCrossRef
98.
Choquet S, Trappe R, Leblond V, Jager U, Davi F, Oertel S (2007) CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica 92:273–274PubMedCrossRef
99.
Gross TG, Bucuvalas JC, Park JR, Greiner TC, Hinrich SH, Kaufman SS et al (2005) Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol 23:6481–6488PubMedCrossRef
100.
Gross TG, Orjuela MA, Perkins SL, Park JR, Lynch JC, Cairo MS et al (2012) Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children’s Oncology Group Report. Am J Transplant 12:3069–3075PubMedPubMedCentralCrossRef
101.
Manez R, Breinig MK, Linden P, Kusne S, Torre-Cisneros J, Wilson J et al (1994) Factors associated with the development of post-transplant lymphoproliferative disease (PTLD) in Epstein-Barr virus (EBV)-seronegative adult liver transplant recipients. Transpl Int 7(Suppl 1):S235–S237PubMedCrossRef
102.
Penn I (1986) Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases. Cancer 58:611–616PubMedCrossRef
103.
Arends MJ, Benton EC, McLaren KM, Stark LA, Hunter JA, Bird CC (1997) Renal allograft recipients with high susceptibility to cutaneous malignancy have an increased prevalence of human papillomavirus DNA in skin tumours and a greater risk of anogenital malignancy. Br J Cancer 75:722–728PubMedPubMedCentralCrossRef
104.
Hartevelt MM, Bavinck JN, Kootte AM, Vermeer BJ, Vandenbroucke JP (1990) Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation 49:506–509PubMedCrossRef
105.
Mullen DL, Silverberg SG, Penn I, Hammond WS (1976) Squamous cell carcinoma of the skin and lip in renal homograft recipients. Cancer 37:729–734PubMedCrossRef
106.
Blohme I, Brynger H (1985) Malignant disease in renal transplant patients. Transplantation 39:23–25PubMed
107.
Penn I (1993) Neoplastic complications of transplantation. Semin Respir Infect 8:233–239PubMed
108.
Smith JM, Martz K, McDonald RA, Harmon WE (2013) Solid tumors following kidney transplantation in children. Pediatr Transplant 17:726–730PubMedCrossRef
109.
Penn I (1995) Primary kidney tumors before and after renal transplantation. Transplantation 59:480–485
110.
Williams JC, Merguerian PA, Schned AR, Morrison PM (1995) Acquired renal cystic disease and renal cell carcinoma in an allograft kidney. J Urol 153:395–396PubMedCrossRef
111.
Baker R, Jardine A, Andrews P (2011) Renal Association Clinical Practice Guideline on post-operative care of the kidney transplant recipient. Nephron Clin Pract 118(Suppl 1):c311–c347PubMedCrossRef
112.
EBPG, Expert Group on Renal Transplantation (2002) European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.3. Cancer risk after renal transplantation. Solid organ cancers: prevention and treatment. Nephrol Dial Transplant 17(Suppl 4):32–34-36
Metadaten
Titel
Pediatric Onco-Nephrology: Time to Spread the Word-Part II: Long-Term Kidney Outcomes in Survivors of Childhood Malignancy and Malignancy after Kidney Transplant
verfasst von
Arwa Nada
Jennifer G Jetton
Publikationsdatum
06.09.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Nephrology / Ausgabe 6/2022
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-021-05172-y

Weitere Artikel der Ausgabe 6/2022

Pediatric Nephrology 6/2022 Zur Ausgabe

Guidelines

Acute kidney injury in pediatric hematopoietic cell transplantation: critical appraisal and consensus

Educational Review

When the progresses in neonatology lead to severe congenital nephron deficit: is there a pilot in the NICU?

Clinical Quiz

A boy with purpura and generalized edema: Answers

Original Article

An initiative to improve pneumococcal immunization counseling in children with nephrotic syndrome

Clinical Quiz

Chediak Higashi syndrome with acute kidney injury: Answers

Clinical Quiz

Chediak Higashi syndrome with acute kidney injury: Questions

Neu im Fachgebiet Pädiatrie

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

16.05.2024 Arterielle Hypertonie in der Pädiatrie Nachrichten

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise